ReviewInternational journal of molecular sciences2018
The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Exploring tumor-derived exosomes as promising antigenic platforms: novel vaccine and immunotherapy strategies for "cold" colorectal cancer.Frontiers in immunology · 2026Review
- Melatonin: a natural guardian in cancer treatment.Frontiers in pharmacology · 2025Review
- Mediation of radiation-induced bystander effect and epigenetic modification: The role of exosomes in cancer radioresistance.Heliyon · 2024Review
- Article
- NK cell-based tumor immunotherapy.Bioactive materials · 2024Review
- Exosomes as crucial emerging tools for intercellular communication with therapeutic potential in ovarian cancer.Future science OA · 2023Review
- The Potential of Topoisomerase Inhibitor-Based Antibody-Drug Conjugates.Pharmaceutics · 2022Review
- Exosome Carrier Effects; Resistance to Digestion in Phagolysosomes May Assist Transfers to Targeted Cells; II Transfers of miRNAs Are Better Analyzed via Systems Approach as They Do Not Fit Conventional Reductionist Stoichiometric Concepts.International journal of molecular sciences · 2022Review
- Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer.Cell death & disease · 2021Article
- Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy.The AAPS journal · 2021Review
- Review
- Exosomal MicroRNAs Mediating Crosstalk Between Cancer Cells With Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in the Tumor Microenvironment.Frontiers in oncology · 2021Review
- An Examination of the Putative Role of Melatonin in Exosome Biogenesis.Frontiers in cell and developmental biology · 2021Review
- Review
- Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance.World journal of gastroenterology · 2019Review
- Role of miRNAs in Melanoma Metastasis.Cancers · 2019Review
- Elevation of miR-191-5p level and its potential signaling pathways in hepatocellular carcinoma: a study validated by microarray and in-house qRT-PCR with 1,291 clinical samples.International journal of clinical and experimental pathology · 2019Article
- Topoisomerases and cancer chemotherapy: recent advances and unanswered questions.F1000Research · 2019Review
- A Review of Exosomes and their Role in The Tumor Microenvironment and Host-Tumor "Macroenvironment".Journal of immunological sciences · 2019Article
- MiR-616-3p modulates cell proliferation and migration through targeting tissue factor pathway inhibitor 2 in preeclampsia.Cell proliferation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years many articles have underlined the key role of nanovesicles, i.e., exosomes, as information carriers among biological systems including cancer. Tumor-derived exosomes (TEXs) are key players in the dynamic crosstalk between cancer cells and the microenvironment while promote immune system control evasion. In fact, tumors are undoubtedly capable of silencing the immune response through multiple mechanisms, including the release of exosomes. TEXs have been shown to boost tumor growth and promote progression and metastatic spreading via suppression or stimulation of the immune response towards cancer cells. The advantage of immunotherapeutic treatment alone over combining immuno- and conventional therapy is currently debated. Understanding the role of tumor exosome-cargo is of crucial importance for our full comprehension of neoplastic immonosuppression and for the construction of novel therapies and vaccines based on (nano-) vesicles. Furthermore, to devise new anti-cancer approaches, diverse groups investigated the possibility of engineering TEXs by conditioning cancer cells’ own cargo. In this review, we summarize the state of art of TEX-based immunomodulation with a particular focus on the molecular function of non-coding family genes, microRNAs. Finally, we will report on recent efforts in the study of potential applications of engineered exosomes in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.